SG11202103191QA - Benzimidazole derivative for use in the treatment of inflammatory disorders - Google Patents
Benzimidazole derivative for use in the treatment of inflammatory disordersInfo
- Publication number
- SG11202103191QA SG11202103191QA SG11202103191QA SG11202103191QA SG11202103191QA SG 11202103191Q A SG11202103191Q A SG 11202103191QA SG 11202103191Q A SG11202103191Q A SG 11202103191QA SG 11202103191Q A SG11202103191Q A SG 11202103191QA SG 11202103191Q A SG11202103191Q A SG 11202103191QA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- inflammatory disorders
- benzimidazole derivative
- benzimidazole
- derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862740748P | 2018-10-03 | 2018-10-03 | |
| PCT/US2019/054293 WO2020072645A1 (en) | 2018-10-03 | 2019-10-02 | Benzimidazole derivative for use in the treatment of inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103191QA true SG11202103191QA (en) | 2021-04-29 |
Family
ID=68468802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103191QA SG11202103191QA (en) | 2018-10-03 | 2019-10-02 | Benzimidazole derivative for use in the treatment of inflammatory disorders |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210369678A1 (en) |
| EP (1) | EP3860593A1 (en) |
| JP (1) | JP2022504293A (en) |
| KR (1) | KR20210100594A (en) |
| CN (1) | CN113382729A (en) |
| AU (1) | AU2019355097A1 (en) |
| CA (1) | CA3114592A1 (en) |
| MX (1) | MX2021003681A (en) |
| SG (1) | SG11202103191QA (en) |
| TW (1) | TW202027745A (en) |
| WO (1) | WO2020072645A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11857543B2 (en) | 2013-06-13 | 2024-01-02 | Akebia Therapeutics, Inc. | Compositions and methods for treating anemia |
| WO2021216530A1 (en) | 2020-04-20 | 2021-10-28 | Akebia Therapeutics, Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| WO2022251563A1 (en) | 2021-05-27 | 2022-12-01 | Keryx Biopharmaceuticals, Inc. | Pediatric formulations of ferric citrate |
| KR20230146812A (en) | 2022-04-13 | 2023-10-20 | 재단법인 대구경북첨단의료산업진흥재단 | Composition for treating inflammatory bowel disease comprising an arylethene derivative as an active ingredient |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0911444B8 (en) | 2008-04-28 | 2021-05-25 | Janssen Pharmaceutica Nv | benzoimidazoles as prolyl hydroxylase inhibitors and pharmaceutical composition comprising them |
-
2019
- 2019-10-02 WO PCT/US2019/054293 patent/WO2020072645A1/en unknown
- 2019-10-02 KR KR1020217012069A patent/KR20210100594A/en unknown
- 2019-10-02 CN CN201980079183.1A patent/CN113382729A/en active Pending
- 2019-10-02 SG SG11202103191QA patent/SG11202103191QA/en unknown
- 2019-10-02 JP JP2021518655A patent/JP2022504293A/en active Pending
- 2019-10-02 CA CA3114592A patent/CA3114592A1/en active Pending
- 2019-10-02 AU AU2019355097A patent/AU2019355097A1/en not_active Abandoned
- 2019-10-02 MX MX2021003681A patent/MX2021003681A/en unknown
- 2019-10-02 US US17/282,108 patent/US20210369678A1/en active Pending
- 2019-10-02 EP EP19798422.2A patent/EP3860593A1/en not_active Withdrawn
- 2019-10-03 TW TW108135867A patent/TW202027745A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3860593A1 (en) | 2021-08-11 |
| CA3114592A1 (en) | 2020-04-09 |
| CN113382729A (en) | 2021-09-10 |
| TW202027745A (en) | 2020-08-01 |
| WO2020072645A1 (en) | 2020-04-09 |
| JP2022504293A (en) | 2022-01-13 |
| MX2021003681A (en) | 2021-08-19 |
| US20210369678A1 (en) | 2021-12-02 |
| KR20210100594A (en) | 2021-08-17 |
| AU2019355097A1 (en) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273693A (en) | Treatment of inflammatory disorders | |
| IL268211A (en) | Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders | |
| MX2018005694A (en) | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof. | |
| SG11202103191QA (en) | Benzimidazole derivative for use in the treatment of inflammatory disorders | |
| HK1258914A1 (en) | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases | |
| HRP20181332T1 (en) | Benzimidazole derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| GB201402070D0 (en) | Pharmaceutical compositions for the treatment of inflammatory disorders | |
| IL284125A (en) | Quinoline derivatives for use in the treatment of inflammation diseases | |
| HK1257169A1 (en) | Indolin-2-one derivatives for use in the treatment of cns and related disorders | |
| SG11201708181RA (en) | Methods for the treatment of inflammatory disorders | |
| IL246855A0 (en) | Agents for use in the treatment of retinal inflammation | |
| IL292690A (en) | Mrgprx2 antagonists for the treatment of inflammatory disorders | |
| IL275349A (en) | Use of hm4di in the treatment of seizure disorders | |
| IL260987A (en) | Treatment and diagnosis of inflammatory disorders | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| ZA201806894B (en) | (+)-azasetron for use in the treatment of ear disorders | |
| EP3371154A4 (en) | Heterocycle derivatives and their use for the treatment of cns disorders | |
| IL276697A (en) | 3beta-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of cannabinoids-related disorders | |
| PT3442537T (en) | (+)-azasetron for use in the treatment of ear disorders | |
| GB201521543D0 (en) | Methods for the treatment of inflammatory disorders | |
| PT3370727T (en) | Non-bioconvertible c3-substituted pregnenolone derivatives for use in the treatment of substance use disorders | |
| GB201513993D0 (en) | Methods for the treatment of inflammatory disorders | |
| GB201513345D0 (en) | Methods for the treatment of Inflammatory disorders | |
| GB201507113D0 (en) | Methods for the treatment of inflammatory disorders | |
| GB201506419D0 (en) | Methods for the treatment of inflammatory disorders |